Haciyev Reşit 
The decentralized science (DeSci) protocol Bio Protocol has raised $6.9 million in seed funding to develop a next-generation “scientific superintelligence” platform. The investment round was led by Maelstrom Fund, the family office of BitMEX co-founder Arthur Hayes.
Rising Momentum in the DeSci Ecosystem
In recent years, decentralized science has become one of the most prominent applications of blockchain technology. Operating in this field, Bio Protocol recently launched its Bio V2 update, aiming to make scientific research more transparent, faster, and accessible.
Bio’s infrastructure enables researchers to transform their work into decentralized AI agents called BioAgents on-chain. This model not only moves research beyond the control of major pharmaceutical companies but also allows broader community funding. As a result, the pace of scientific progress accelerates while costs are reduced.
Leading Crypto Investors Join the Round
The $6.9 million seed round attracted some of the most notable investors in the sector. While Maelstrom Fund led the financing, Mechanism Capital, Animoca Brands, Zee Prime Capital, Panga Capital, Mirana Ventures, Foresight Ventures, and Big Brain Holdings also participated.
This participation highlights that Bio is not just a DeSci startup but is rapidly emerging as a strategic player at the intersection of Web3, AI, and healthcare technologies.
Official Statement
Paul Kohlhaas, Founder and CEO of Bio Protocol, shared the company’s vision:
“Just as digital publishing platforms allowed content creators to build audiences and earn outside of traditional media, Bio’s infrastructure can give scientists the power to conduct research and monetize it outside of traditional pharmaceutical structures. Our goal is to accelerate scientific progress and build a system that can benefit humanity faster.”
Expansion Plans with Fresh Capital
The newly raised $6.9 million will be used to expand Bio Protocol globally. In the coming period, the company plans to launch new BioAgents in areas such as dermatology, microbiome health, brain health, and men’s health.
Additionally, with the Bio V2 update, the platform introduces staking, the BioXP rewards program, and rapid fundraising tools for researchers. These mechanisms will help scientific projects receive funding more quickly while ensuring researchers remain actively engaged in the ecosystem.
Investor’s Comment
Arthur Hayes, Founder and CIO of Maelstrom Fund, emphasized Bio’s potential to reshape scientific research:
“Bio Protocol could become a category-defining launchpad for community-driven scientific research. If successful, it will not only be a launchpad but also mark the birth of a new research marketplace native to artificial intelligence.”
With this new funding, Bio Protocol is taking a critical step toward democratizing and accelerating scientific research. Traditionally controlled by large funds and pharmaceutical companies, research processes are now becoming more transparent, fair, and accessible thanks to blockchain and AI.
You can also freely share your thoughts and comments about the topic in the comment section. Additionally, don’t forget to follow us on our Telegram, YouTube, and Twitter channels for the latest news and updates.